Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 91 results for cholesterol

  1. Care and support of people growing older with learning disabilities (NG96)

    This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.

    NICE guideline
    Published
    11 April 2018
    View recommendations

    Sections for NG96

  2. Implantation of a duodenal–jejunal bypass sleeve for managing obesity (IPG471)

    Evidence-based recommendations on implantation of a duodenal-jejunal bypass sleeve for managing obesity. This involves attaching a sleeve to the upper part of the bowel to slow digestion.

    Interventional procedures guidance
    Published
    27 November 2013
    View recommendations

    Sections for IPG471

  3. Stroke Prevention in Atrial Fibrillation (AF) Protect and Perfect – Optimising anticoagulation treatment

    Including: Atrial Fibrillation, Heart Failure, Cardiac Rehabilitation, Cholesterol and Familial Hypercholesterolemia. National targets...

    Shared learning
    Last updated
    10 May 2021

  4. Turning the tide on ineffective prescribing of glucagon like peptide (GLP-1) mimetics in type 2 diabetes in East Sussex

    reviews was diabetes medication optimisation to include blood pressure and cholesterol management; however, other medication issues...

    Shared learning
    Last updated
    23 May 2019

  5. Laser lithotripsy for difficult-to-treat bile duct stones (IPG699)

    Evidence-based recommendations on laser lithotripsy for difficult-to-treat bile duct stones in adults. This involves breaking up the stones using laser light.

    Interventional procedures guidance
    Published
    23 June 2021
    View recommendations

    Sections for IPG699

  6. Electrohydraulic lithotripsy for difficult-to-treat bile duct stones (IPG698)

    Evidence-based recommendations on electrohydraulic lithotripsy for difficult-to-treat bile duct stones in adults. This involves breaking up the stone with soundwaves.

    Interventional procedures guidance
    Published
    26 May 2021
    View recommendations

    Sections for IPG698

  7. New opportunities for the treatment of hyperlipidaemia: Initiation of PCSK9 monoclonal antibodies utilising a multi-disciplinary approach.

    patients are failing to achieve the 50% reduction in low-density lipoprotein cholesterol (LDL-c) from baseline as recommended by NICE...

    Shared learning
    Published
    21 March 2019

  8. How effective and cost effective are different types of exercise referral scheme? Compare the relative effects of different models in controlled studies. Include health-related quality of life as an outcome. Compare exercise referral schemes that vary by: - setting – for example, home-based, gym-based, community-based or outdoors - intensity and duration – for example, a 12-week scheme involving 1 session a week, or a 6-week scheme involving 4 1-hour sessions per week - the techniques used, for example, some use additional 'supportive' techniques such as 'motivational interviewing' and education sessions - the target group, for example, people who are overweight and obese, people with raised blood pressure or cholesterol levels or those experiencing mild depression, anxiety or stress; or by age, gender, race or socioeconomic status - other scheme characteristics including: design, content and delivery; referral mechanisms; choice of activity; cost and qualifications of instructors; and whether it is commissioned and delivered by an NHS, non-NHS or community-based organisation.

    people who are overweight and obese, people with raised blood pressure or cholesterol levels or those experiencing mild depression,...

    Research recommendation
    Published
    9 June 2015

  9. Weight management: overweight register (IND237)

    This indicator covers the establishing and maintaining of a register of patients aged 18 or over with a BMI of 23 kg/m2 or more (or 25 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM221

    General practice indicators suitable for use in QOF
    Published
    7 September 2022

  10. Weight management: obesity register (IND238)

    This indicator covers the establishing and maintaining of a register of patients aged 18 or over with a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM222

    General practice indicators suitable for use in QOF
    Published
    7 September 2022

  11. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

    Technology appraisal guidance
    Published
    13 July 2022
    View recommendations

    Sections for TA805

  12. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

    This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

    NICE guideline
    Last updated
    13 April 2022
    View recommendations

    Sections for NG128

  13. PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes (MIB312)

    NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .

    Medtech innovation briefing
    Published
    13 December 2022

  14. LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)

    NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .

    Medtech innovation briefing
    Published
    21 February 2023

  15. Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

    Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 February 2013